Aleitinib hydrochloride capsule is a targeted agent for the treatment of non-small cell lung cancer, and is indicated as a single agent for the treatment of patients with locally advanced or metastatic non-small cell lung cancer that is positive for anaplastic lymphoma kinase (ALK).
Aleitinib is a highly selective and potent ALK (anaplastic lymphoma kinase) and RET (a proto-oncogene) tyrosine kinase inhibitor. Aleitinib inhibits ALK tyrosine kinase activity and induces apoptosis in tumor cells, so it can be used in targeted therapy for non-small cell lung cancer.
Common adverse effects of taking alectinib include constipation, edema (peripheral edema, generalized edema, eyelid edema, and periorbital edema), myalgia, nausea, elevated bilirubin, anemia, and rash (rash, maculopapular rash, acne-like dermatitis, erythema, generalized rash, papulopapular rash, pruritic rash, and maculopapular rash). The use of this medicine is contraindicated in patients who are allergic to aleitinib.
If you need to use Aleitinib, do so under the supervision of a physician and do not take the drug on your own.